Diet Pill May Also Help Reduce Liver Damage
Acomplia (rimonabant) works by blocking the CB1 receptors in the brain and fat tissue. cannabinoids latch on to the CB1 receptors and send out a signal that prompts people to eat more. These receptors tend to be more active in overweight people.
In clinical trials. Acomplia (rimonabant) has been shown to help people with weight loss when taken regularly as a slimming aid. There is also evidence suggesting that it also reduces the amount of visceral fat in the abdominal cavity which is linked to heart disease and diabetes.
Recent research at Sanofi-Aventis the developers of rimonabant, suggests yet another possible health benefit for users of the controversial diet pill Acomplia (rimonabant). Apparently it can also reduce liver damage associated with obesity, which in turn can lead to cirrhosis.
The study, led by Mohammed Bensaid of Sanofi-Aventis, was carried out on obese male rats who were given rimonabant orally for 8 weeks. Test results showed that treatment reduced liver enlargement, eradicated hepatic steatosis, and reduced the blood levels of enzyme markers that suggest liver damage. Other benefits were reduced levels of hepatic TNFa, a pro-inflammatory protein considered responsible for inducing insulin resistance in the liver.
The animal study revealed little or no improvement in the control rats that were fed the same diet but did not receive rimonabant, indicating that the benefits were attributable to the diet pill rather than the diet.
Researchers believe “that the multi-protective effects of Acomplia (rimonabant) may be attributable to the reduction in pro-inflammatory cytokines, and the increase in anti-inflammatory and protective cytokines. This suggests a potential medical application for Acomplia (rimonabant) in the treatment of liver diseases associated with obesity and the metabolic syndrome.”
Jeff Talbot
Tags: acomplia, diet pill, slimming, weight loss
Leave a Reply